[{"Assets_0_Q3_USD":210287000.0,"CommonStockSharesOutstanding_0_Q3_shares":304089718.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-62400000.0,"NetIncomeLoss_1_Q3_USD":-24471000.0,"NetIncomeLoss_3_Q3_USD":-82776000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":295595000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":291526000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":295595000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":291526000.0,"StockholdersEquity_0_Q3_USD":-52826000.0,"EarningsPerShareBasic_1_Q3_USD":-0.08,"EarningsPerShareBasic_3_Q3_USD":-0.28,"EarningsPerShareDiluted_1_Q3_USD":-0.08,"EarningsPerShareDiluted_3_Q3_USD":-0.28,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":55323000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":151884000.0,"Ticker":"AMRN","CIK":"897448","name":"AMARIN CORP PLCUK","OfficialName":"Amarin Corporation plc","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265593617.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181101"}]